首页> 外文期刊>Plant Biotechnology Journal >Biochemical composition of haemagglutinin?¢????based influenza virus?¢????like particle vaccine produced by transient expression in tobacco plants
【24h】

Biochemical composition of haemagglutinin?¢????based influenza virus?¢????like particle vaccine produced by transient expression in tobacco plants

机译:在烟草植物中瞬时表达产生的基于血凝素的流感病毒样颗粒疫苗的生化组成

获取原文
           

摘要

Influenza virus?¢????like particles (VLPs) are noninfectious particles resembling the influenza virus representing a promising vaccine alternative to inactivated influenza virions as antigens. Medicago inc. has developed a plant?¢????based VLP manufacturing platform allowing the large?¢????scale production of GMP?¢????grade influenza VLPs. In this article, we report on the biochemical compositions of these plant?¢????based influenza candidate vaccines, more particularly the characterization of the N?¢???? glycan profiles of the viral haemagglutinins H1 and H5 proteins as well as the tobacco?¢????derived lipid content and residual impurities. Mass spectrometry analyses showed that all N?¢???? glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant?¢????specific complex?¢????type N?¢???? glycans having core ???±(1,3)?¢????fucose, core ???2(1,2)?¢????xylose epitopes and Lewis a extensions. Previous phases I and II clinical studies have demonstrated that no hypersensibility nor induction of IgG or IgE directed against these glycans was observed. In addition, this article showed that the plant?¢????made influenza vaccines are highly pure VLPs preparations while detecting no protein contaminants coming either from Agrobacterium or from the enzymes used for the enzyme?¢????assisted extraction process. In contrast, VLPs contain few host cell proteins and glucosylceramides associated with plant lipid rafts. Identification of such raft markers, together with the type of host cell impurity identified, confirmed that the mechanism of VLP formation in planta is similar to the natural process of influenza virus assembly in mammals.
机译:流感病毒样颗粒(VLP)是类似于流感病毒的非感染性颗粒,代表了灭活流感病毒颗粒作为抗原的有希望的疫苗替代品。 Medicago inc。已经开发了一种基于工厂的VLP制造平台,该平台可以大规模生产GMP级的流感VLP。在本文中,我们报告了这些基于植物的流感候选疫苗的生化成分,特别是N ????的特征。病毒血凝素H1和H5蛋白的聚糖谱以及烟草的血脂含量和残留杂质。质谱分析表明所有的N 2+均存在。重组血凝素细胞外结构域的糖基化位点携带植物???特异性复合物?????具有核心±(1,3)-岩藻糖,核心核心2(1,2)-β-木糖表位和Lewis a延伸的聚糖。先前的I和II期临床研究表明,未观察到针对这些聚糖的超敏反应或IgG或IgE的诱导。另外,本文表明,植物制成的流感疫苗是高纯度的VLP制剂,同时没有检测到来自农杆菌或用于辅助提取过程的酶的蛋白质污染物。相比之下,VLP含有很少的宿主细胞蛋白和与植物脂质筏相关的葡萄糖基神经酰胺。对这类筏标记的鉴定以及鉴定出的宿主细胞杂质的类型,证实了植物体内VLP形成的机制与哺乳动物中流感病毒装配的自然过程相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号